Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Lymphoma
-
-
Combination Chemotherapy in Treating Patients With Non-Hodgkin’s Lymphoma or Acute Lymphocytic Leukemia
-
Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin’s Lymphoma
-
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin’s Lymphoma
-
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin’s Lymphoma That is Not Refractory to Rituximab
-
Cladribine in Patients With Mantle Cell Lymphoma
-
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin’s Lymphoma
-
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
-
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Categories
Alliance Committee
Browse by Year